a76df2f9_docrine_Cancer_Research___CFCF__Status
[Title] A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors [Phase] I/II [Conditions] Pancreatic Neuroendocrine Tumor [State] MO [Status] 
Enrolling
N o t R e c r u i t i n g
E n r o l l i n g
Clinical Trials Finder | Carcinoid and Pancreatic Neuroendocrine Cancer Research | CFCF
Status